ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 101 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q3 2016. The put-call ratio across all filers is 1.42 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $910,000 | -42.4% | 33,837 | -23.6% | 0.00% | – |
| Q2 2023 | $1,579,000 | +194.0% | 44,301 | +109.3% | 0.00% | – |
| Q1 2023 | $537,000 | -84.1% | 21,170 | -74.5% | 0.00% | -100.0% |
| Q4 2022 | $3,369,000 | +58.8% | 83,058 | +29.3% | 0.00% | 0.0% |
| Q3 2022 | $2,122,000 | -0.7% | 64,256 | +5.9% | 0.00% | 0.0% |
| Q2 2022 | $2,136,000 | -25.7% | 60,672 | -2.9% | 0.00% | 0.0% |
| Q1 2022 | $2,873,000 | -50.7% | 62,474 | -28.9% | 0.00% | 0.0% |
| Q4 2021 | $5,828,000 | +32.1% | 87,896 | +24.4% | 0.00% | 0.0% |
| Q3 2021 | $4,411,000 | -12.2% | 70,633 | +16.4% | 0.00% | 0.0% |
| Q2 2021 | $5,025,000 | +6.6% | 60,673 | -14.7% | 0.00% | 0.0% |
| Q1 2021 | $4,715,000 | -29.6% | 71,098 | -18.5% | 0.00% | -50.0% |
| Q4 2020 | $6,693,000 | +52.1% | 87,240 | -17.6% | 0.00% | 0.0% |
| Q3 2020 | $4,401,000 | -24.9% | 105,903 | -21.9% | 0.00% | 0.0% |
| Q2 2020 | $5,857,000 | +73.4% | 135,603 | +15.5% | 0.00% | 0.0% |
| Q1 2020 | $3,378,000 | -56.7% | 117,374 | -4.6% | 0.00% | -33.3% |
| Q4 2019 | $7,803,000 | +308.3% | 123,030 | +81.5% | 0.00% | +200.0% |
| Q3 2019 | $1,911,000 | +1.2% | 67,782 | -4.9% | 0.00% | 0.0% |
| Q2 2019 | $1,889,000 | +46.1% | 71,303 | +1.2% | 0.00% | 0.0% |
| Q1 2019 | $1,293,000 | +114.4% | 70,461 | +45.1% | 0.00% | – |
| Q4 2018 | $603,000 | +92.0% | 48,567 | +196.4% | 0.00% | – |
| Q3 2018 | $314,000 | +65.3% | 16,388 | +17.6% | 0.00% | – |
| Q2 2018 | $190,000 | +400.0% | 13,932 | +162.0% | 0.00% | – |
| Q1 2018 | $38,000 | +280.0% | 5,317 | +87.7% | 0.00% | – |
| Q4 2017 | $10,000 | -67.7% | 2,832 | -60.7% | 0.00% | – |
| Q3 2017 | $31,000 | +520.0% | 7,208 | +127.9% | 0.00% | – |
| Q2 2017 | $5,000 | -72.2% | 3,163 | -68.3% | 0.00% | – |
| Q1 2017 | $18,000 | +12.5% | 9,984 | -5.5% | 0.00% | – |
| Q4 2016 | $16,000 | -70.4% | 10,564 | +42.6% | 0.00% | – |
| Q3 2016 | $54,000 | +5.9% | 7,408 | -24.1% | 0.00% | – |
| Q2 2016 | $51,000 | – | 9,758 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WESTERN FINANCIAL Corp | 820,346 | $62,945,000 | 41.38% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $250,206,000 | 32.27% |
| Aquilo Capital Management, LLC | 365,926 | $28,078,000 | 5.84% |
| L1 Capital Pty Ltd | 298,687 | $23,127,000 | 4.32% |
| First Light Asset Management, LLC | 704,449 | $54,052,000 | 4.00% |
| ACUTA CAPITAL PARTNERS, LLC | 139,000 | $10,665,000 | 2.90% |
| Evolutionary Tree Capital Management, LLC | 48,265 | $3,703,000 | 2.82% |
| Parkman Healthcare Partners LLC | 127,171 | $9,758,000 | 2.50% |
| Capital Impact Advisors, LLC | 88,183 | $6,766,000 | 1.66% |
| Tri Locum Partners LP | 56,003 | $4,297,000 | 1.56% |